G-20 Determines World's Energy Fate

Source: CNET, Candace Lombardi (12/8/10)

"Aggressive clean-energy policy would see $190B invested in industry by 2020."

The G-20 nations have the largest impact on the future of clean energy as they account for 90% of global clean-energy investment. China leads the G-20 in clean-energy investment and development and may do so for the next 10 years.

Pew's "Global Clean Power: A $2.3 Trillion Opportunity" report offers predictions for the future of clean-energy investment based on which policies are adopted by the G-20 member nations. It lays out how global private investment in clean energy would play out under three different scenarios:

If current policies remain in place;
If the Copenhagen 2009 pledges are carried out; and
If more aggressive energy policies are adopted.

According to a Pew report released earlier this year, China was the largest clean-energy investor in 2009 at $34.6 billion. The U.S. came in second with $18.6B, followed by the UK with $11.2B. China continues to lead in the report released today, which predicts worldwide private investment in clean-energy projects will likely total $1.7 trillion by 2020.

If the G-20 governments adopt more aggressive clean-energy policies, that investment could increase by $546B to total $2.3 trillion.

India, also a rising star in the energy sector, is forecast to move from 10th to 3rd in rank by 2020, no matter which scenario comes true. India, the U.S. and UK are the three G-20 countries where a lack of clean-energy policies has afforded much room for possible growth in the coming years.

"Cumulatively, the U.S. has the potential to attract $342 billion in private clean-energy investments over the next decade," the report said.

Wind has proved to be the most cost-competitive, large-scale clean-energy option. The report predicts the successful wind sector will win even more investment compared to solar, geothermal and hydro. Under aggressive clean-energy policy adoption, the industry would see $190B invested by 2020.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.